皮肤鳞状细胞癌诊疗专家共识（2021）

doi:10.35541/cjd.20201140

Abstract

Abstract: 【Abstract】 Cutaneous squamous cell carcinoma （cSCC） is one of the most common non-melanoma skin cancers. In recent years, with the in-depth study of its pathogenesis, as well as the development of diagnostic technology, Mohs micrographic surgery, targeted therapy and immunotherapy, great progress has been made in the diagnosis and treatment of cSCC. Based on recent domestic and international relevant literature and guidelines, and combined with the availability of diagnostic and therapeutic methods in China, this consensus focuses on clinical manifestations, classification, biopsy pathology and report standards, risk factor assessment, grading, staging, and standardized treatment of cSCC, and aims to provide a reference for the diagnosis and treatment of cSCC in clinical practice.

Key words: Neoplasms, squamous cell, Skin, Diagnosis, Clinical protocols, Expert consensus

Skin Tumor Research Center, Chinese Society of Dermatology, Subcommittee on Skin Tumor, China Dermatologist Association. Consensus on diagnosis and treatment of cutaneous squamous cell carcinoma （2021）[J]. Chinese Journal of Dermatology, 2021, 54(8): 653-664.doi:10.35541/cjd.20201140

References ［77］

［1］	Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability⁃adjusted life⁃years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study［J］. JAMA Oncol, 2017,3（4）:524⁃548. doi: 10.1001/jamaoncol. 2016.5688.
［2］	GBD 2016 Healthcare Access and Quality Collaborators. Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016［J］. Lancet, 2018,391（10136）:2236⁃2271. doi: 10.1016/S0140⁃6736（18）30994⁃2.
［3］	National Comprehensive Cancer Network. Squamous cell skin cancer, version 1.2021, NCCN clinical practice guidelines in oncology［Z/OL］. （2021⁃02⁃05）［2021⁃04⁃07］. https://www.nccn.org/professionals/physician_gls/pdf/squamous.pdf.
［4］	Stratigos AJ, Garbe C, Dessinioti C, et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: part 1. Epidemiology, diagnostics and prevention［J］. Eur J Cancer, 2020,128:60⁃82. doi: 10.1016/j.ejca.2020.01.007.
［5］	Stratigos AJ, Garbe C, Dessinioti C, et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: part 2. Treatment［J］. Eur J Cancer, 2020,128:83⁃102. doi: 10.1016/j.ejca.2020.01.008.
［6］	Elder DE, Massi D, Scolyer RA, et al. WHO classification of skin tumours［M］. 4th ed. Lyon:IARC Press, 2018:470.
［7］	国务院人口普查办公室, 国家统计局人口和就业统计司. 中国2010年人口普查资料［M］. 北京: 中国统计出版社, 2012:265. http://www.stats.gov.cn/tjsj/pcsj/rkpc/6rp/indexch.htm.
［8］	涂庆峰, 吕婷, 赖永贤, 等. 上海市某社区老年人皮肤肿瘤流行病学研究［J］. 老年医学与保健, 2013,19（3）:142⁃145,148. doi: 10.3969/j.issn.1008⁃8296.2013⁃05.
［9］	高天文, 孙东杰, 李春英, 等. 中国西部两医院1905例皮肤恶性肿瘤回顾分析［J］. 北京大学学报（医学版）, 2004,36（5）:469⁃472. doi: 10.3321/j.issn:1671⁃167X.2004.05.005.
［10］	Wikonkal NM, Brash DE. Ultraviolet radiation induced signature mutations in photocarcinogenesis［J］. J Investig Dermatol Symp Proc, 1999,4（1）:6⁃10. doi: 10.1038/sj.jidsp.56 40173.
［11］	Lindelöf B, Sigurgeirsson B, Gäbel H, et al. Incidence of skin cancer in 5356 patients following organ transplantation［J］. Br J Dermatol, 2000,143（3）:513⁃519.
［12］	Jensen P, Hansen S, Møller B, et al. Skin cancer in kidney and heart transplant recipients and different long⁃term immunosuppressive therapy regimens［J］. J Am Acad Dermatol, 1999,40（2 Pt 1）:177⁃186. doi: 10.1016/s0190⁃9622（99）70185⁃4.
［13］	Hartevelt MM, Bavinck JN, Kootte AM, et al. Incidence of skin cancer after renal transplantation in the Netherlands［J］. Transplantation, 1990,49（3）:506⁃509. doi: 10.1097/00007890⁃199003000⁃00006.
［14］	Bolognia JL, Schaffer JV, Cerroni L. 皮肤病学［M］. 朱学骏, 王宝玺, 孙建方, 等, 译. 4版. 北京: 北京大学医学出版社, 2019:2077⁃2079.
［15］	Zhao H, Shu G, Wang S. The risk of non⁃melanoma skin cancer in HIV⁃infected patients: new data and meta⁃analysis［J］. Int J STD AIDS, 2016,27（7）:568⁃575. doi: 10.1177/095646241558 6316.
［16］	Torchia D, Massi D, Caproni M, et al. Multiple cutaneous precanceroses and carcinomas from combined iatrogenic/professional exposure to arsenic［J］. Int J Dermatol, 2008,47（6）:592⁃593. doi: 10.1111/j.1365⁃4632.2008.03547.x.
［17］	Yuspa SH. Cutaneous chemical carcinogenesis［J］. J Am Acad Dermatol, 1986,15（5 Pt 1）:1031⁃1044. doi: 10.1016/s0190⁃9622 （86）70267⁃3.
［18］	Ratushny V, Gober MD, Hick R, et al. From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma［J］. J Clin Invest, 2012,122（2）:464⁃472. doi: 10.1172/JCI57415.
［19］	Harwood CA, Proby CM, Inman GJ, et al. The promise of genomics and the development of targeted therapies for cutaneous squamous cell carcinoma［J］. Acta Derm Venereol, 2016,96（1）:3⁃16. doi: 10.2340/00015555⁃2181.
［20］	Di Nardo L, Pellegrini C, Di Stefani A, et al. Molecular genetics of cutaneous squamous cell carcinoma: perspective for treatment strategies［J］. J Eur Acad Dermatol Venereol, 2020,34（5）:932⁃941. doi: 10.1111/jdv.16098.
［21］	Brash DE, Rudolph JA, Simon JA, et al. A role for sunlight in skin cancer: UV⁃induced p53 mutations in squamous cell carcinoma［J］. Proc Natl Acad Sci U S A, 1991,88（22）:10124⁃10128. doi: 10.1073/pnas.88.22.10124.
［22］	South AP, Purdie KJ, Watt SA, et al. NOTCH1 mutations occur early during cutaneous squamous cell carcinogenesis［J］. J Invest Dermatol, 2014,134（10）:2630⁃2638. doi: 10.1038/jid. 2014.154.
［23］	Wang NJ, Sanborn Z, Arnett KL, et al. Loss⁃of⁃function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma［J］. Proc Natl Acad Sci U S A, 2011,108（43）:17761⁃17766. doi: 10.1073/pnas.1114669108.
［24］	Lee CS, Bhaduri A, Mah A, et al. Recurrent point mutations in the kinetochore gene KNSTRN in cutaneous squamous cell carcinoma［J］. Nat Genet, 2014,46（10）:1060⁃1062. doi: 10.1038/ ng.3091.
［25］	Robert C, Arnault JP, Mateus C. RAF inhibition and induction of cutaneous squamous cell carcinoma［J］. Curr Opin Oncol, 2011,23（2）:177⁃182. doi: 10.1097/CCO.0b013e3283436e8c.
［26］	Li YY, Hanna GJ, Laga AC, et al. Genomic analysis of metastatic cutaneous squamous cell carcinoma［J］. Clin Cancer Res, 2015,21（6）:1447⁃1456. doi: 10.1158/1078⁃0432.CCR⁃14⁃1773.
［27］	Uribe P, Gonzalez S. Epidermal growth factor receptor （EGFR） and squamous cell carcinoma of the skin: molecular bases for EGFR⁃targeted therapy［J］. Pathol Res Pract, 2011,207（6）:337⁃342. doi: 10.1016/j.prp.2011.03.002.
［28］	Asgari MM, Toland AE, Arron ST. IRF4 polymorphism is associated with cutaneous squamous cell carcinoma in organ transplant recipients: a pigment⁃independent phenomenon［J］. J Invest Dermatol, 2017,137（1）:251⁃253. doi: 10.1016/j.jid.2016. 07.038.
［29］	Chahal HS, Lin Y, Ransohoff KJ, et al. Genome⁃wide association study identifies novel susceptibility loci for cutaneous squamous cell carcinoma［J］. Nat Commun, 2016,7:12048. doi: 10.1038/ncomms12048.
［30］	Asgari MM, Wang W, Ioannidis NM, et al. Identification of susceptibility loci for cutaneous squamous cell carcinoma［J］. J Invest Dermatol, 2016,136（5）:930⁃937. doi: 10.1016/j.jid.2016. 01.013.
［31］	Sarin KY, Lin Y, Daneshjou R, et al. Genome⁃wide meta⁃analysis identifies eight new susceptibility loci for cutaneous squamous cell carcinoma［J］. Nat Commun, 2020,11（1）:820. doi: 10.1038/s41467⁃020⁃14594⁃5.
［32］	Boateng B, Hornstein OP, von den Driesch P, et al. Multiple keratoacanthomas （Witten⁃Zak type） in prurigo simplex subacuta［J］. Hautarzt, 1995,46（2）:114⁃117. doi: 10.1007/s001 050050219.
［33］	张聪聪, 陈浩. Muir⁃Torre综合征的研究进展［J］. 中国麻风皮肤病杂志, 2020,36（4）:253⁃256. doi: 10.12144/zgmfskin20200 4253.
［34］	国家皮肤与免疫疾病临床医学研究中心, 中国医师协会皮肤科医师分会皮肤外科亚专业委员会, 中国中西医结合学会皮肤性病学专业委员会皮肤影像学组, 等. 常见皮肤病高频皮肤超声诊断专家共识［J］. 中国医学前沿杂志（电子版）, 2019,11（8）:23⁃28. doi: 10.12037/YXQY.2019.08⁃04.
［35］	中国中西医结合学会皮肤性病学分会皮肤影像学组. 常见非黑素细胞性皮肤肿瘤皮肤镜特征与组织病理表现的对应关系专家共识［J］. 中华皮肤科杂志, 2021,54（1）:10⁃18. doi: 10.35541/cjd.20200446.
［36］	高天文, 王雷, 廖文俊. 实用皮肤组织病理学［M］. 2版. 北京: 人民卫生出版社, 2018:701.
［37］	Henderson SA, Torres⁃Cabala CA, Curry JL, et al. p40 is more specific than p63 for the distinction of atypical fibroxanthoma from other cutaneous spindle cell malignancies［J］. Am J Surg Pathol, 2014,38（8）:1102⁃1110. doi: 10.1097/PAS.0000000000 000245.
［38］	Bice TC, Tran V, Merkley MA, et al. Disease⁃specific survival with spindle cell carcinoma of the head and neck［J］. Otolaryngol Head Neck Surg, 2015,153（6）:973⁃980. doi: 10. 1177/0194599815594360.
［39］	Fu JM, McCalmont T, Yu SS. Adenosquamous carcinoma of the skin: a case series［J］. Arch Dermatol, 2009,145（10）:1152⁃1158. doi: 10.1001/archdermatol.2009.218.
［40］	Al⁃Arashi MY, Byers HR. Cutaneous clear cell squamous cell carcinoma in situ: clinical, histological and immunohisto⁃chemical characterization［J］. J Cutan Pathol, 2007,34（3）:226⁃233. doi: 10.1111/j.1600⁃0560.2006.00593.x.
［41］	Chung HJ, Wolpowitz D, Scott G, et al. Squamous cell carcinoma with osteoclast⁃like giant cells: a morphologically heterologous group including carcinosarcoma and squamous cell carcinoma with stromal changes［J］. J Cutan Pathol, 2016,43（2）:148⁃157. doi: 10.1111/cup.12607.
［42］	Stratigos A, Garbe C, Lebbe C, et al. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus⁃based interdisciplinary guideline［J］. Eur J Cancer, 2015,51（14）:1989⁃2007. doi: 10.1016/j.ejca.2015.06.110.
［43］	Batra RS, Kelley LC. Predictors of extensive subclinical spread in nonmelanoma skin cancer treated with Mohs micrographic surgery［J］. Arch Dermatol, 2002,38（8）:1043⁃1051. doi: 10.1001/ archderm.138.8.1043.
［44］	Leibovitch I, Huilgol SC, Selva D, et al. Cutaneous squamous cell carcinoma treated with Mohs micrographic surgery in Australia I. Experience over 10 years［J］. J Am Acad Dermatol, 2005,53（2）:253⁃260. doi: 10.1016/j.jaad.2005.02.059.
［45］	Tschetter AJ, Campoli MR, Zitelli JA, et al. Long⁃term clinical outcomes of patients with invasive cutaneous squamous cell carcinoma treated with Mohs micrographic surgery: a 5⁃year, multicenter, prospective cohort study［J］. J Am Acad Dermatol, 2020,82（1）:139⁃148. doi: 10.1016/j.jaad.2019.06.1303.
［46］	张良. Mohs显微描记手术治疗皮肤恶性肿瘤56例临床分析［J］. 中国皮肤性病学杂志, 2012,26（3）:268⁃270.
［47］	Breuninger H, Brantsch K, Eigentler T, et al. Comparison and evaluation of the current staging of cutaneous carcinomas［J］. J Dtsch Dermatol Ges, 2012,10（8）:579⁃586. doi: 10.1111/j.1610⁃0387.2012.07896.x.
［48］	Tejera⁃Vaquerizo A, Cañueto J, Llombart B, et al. Predictive value of sentinel lymph node biopsy in cutaneous squamous cell carcinoma based on the AJCC⁃8 and Brigham and Women′s Hospital Staging Criteria［J］. Dermatol Surg, 2020,46（7）:857⁃862. doi: 10.1097/DSS.0000000000002170.
［49］	Durham AB, Lowe L, Malloy KM, et al. Sentinel lymph node biopsy for cutaneous squamous cell carcinoma on the head and neck［J］. JAMA Otolaryngol Head Neck Surg, 2016,142（12）:1171⁃1176. doi: 10.1001/jamaoto.2016.1927.
［50］	Work Group, Invited Reviewers, Kim J, et al. Guidelines of care for the management of cutaneous squamous cell carcinoma［J］. J Am Acad Dermatol, 2018,78（3）:560⁃578. doi: 10.1016/j.jaad. 2017.10.007.
［51］	Chitwood K, Etzkorn J, Cohen G. Topical and intralesional treatment of nonmelanoma skin cancer: efficacy and cost comparisons［J］. Dermatol Surg, 2013,39（9）:1306⁃1316. doi: 10. 1111/dsu.12300.
［52］	Love WE, Bernhard JD, Bordeaux JS. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review［J］. Arch Dermatol, 2009,145（12）:1431⁃1438. doi: 10.1001/archdermatol.2009.291.
［53］	Lansbury L, Bath⁃Hextall F, Perkins W, et al. Interventions for non⁃metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies［J］. BMJ, 2013,347:f6153. doi: 10.1136/bmj.f6153.
［54］	Zaar O, Fougelberg J, Hermansson A, et al. Effectiveness of photodynamic therapy in Bowen′s disease: a retrospective observational study in 423 lesions［J］. J Eur Acad Dermatol Venereol, 2017,31（8）:1289⁃1294. doi: 10.1111/jdv.14164.
［55］	Morton C, Horn M, Leman J, et al. Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or fluorouracil for treatment of squamous cell carcinoma in situ: results of a multicenter randomized trial［J］. Arch Dermatol, 2006,142（6）:729⁃735. doi: 10.1001/archderm.142.6.729.
［56］	葛新红, 焦亚宁, 董灵娣, 等. 5⁃氨基酮戊酸光动力治疗皮肤肿瘤的疗效观察［J］. 中国皮肤性病学杂志, 2015,29（10）:1035⁃1037. doi: 10.13735/j.cjdv.1001⁃7089.201411108.
［57］	Likhacheva A, Awan M, Barker CA, et al. Definitive and postoperative radiation therapy for basal and squamous cell cancers of the skin: executive summary of an American Society for Radiation Oncology Clinical Practice Guideline［J］. Pract Radiat Oncol, 2020,10（1）:8⁃20. doi: 10.1016/j.prro.2019.10.014.
［58］	Ribero S, Stucci LS, Daniels GA, et al. Drug therapy of advanced cutaneous squamous cell carcinoma: is there any evidence?［J］. Curr Opin Oncol, 2017,29（2）:129⁃135. doi: 10. 1097/CCO.0000000000000359.
［59］	Guthrie TH Jr, Porubsky ES, Luxenberg MN, et al. Cisplatin⁃based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy［J］. J Clin Oncol, 1990,8（2）:342⁃346. doi: 10.1200/JCO.1990.8.2.342.
［60］	Wollina U, Hansel G, Koch A, et al. Oral capecitabine plus subcutaneous interferon alpha in advanced squamous cell carcinoma of the skin［J］. J Cancer Res Clin Oncol, 2005,131（5）:300⁃304. doi: 10.1007/s00432⁃004⁃0656⁃6.
［61］	Cartei G, Cartei F, Interlandi G, et al. Oral 5⁃fluorouracil in squamous cell carcinoma of the skin in the aged［J］. Am J Clin Oncol, 2000,23（2）:181⁃184. doi: 10.1097/00000421⁃200004000⁃ 00015.
［62］	Shin DM, Glisson BS, Khuri FR, et al. Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer［J］. J Clin Oncol, 2002,20（2）:364⁃370. doi: 10.1200/JCO.2002.20.2.364.
［63］	Mecca C, Ponzetti A, Caliendo V, et al. Complete response of metastatic cutaneous squamous cell carcinoma to cetuximab plus paclitaxel［J］. Eur J Dermatol, 2012,22（6）:758⁃761. doi: 10. 1684/ejd.2012.1845.
［64］	Trodello C, Pepper JP, Wong M, et al. Cisplatin and cetuximab treatment for metastatic cutaneous squamous cell carcinoma: a systematic review［J］. Dermatol Surg, 2017,43（1）:40⁃49. doi: 10. 1097/DSS.0000000000000799.
［65］	Jarkowski A 3rd, Hare R, Loud P, et al. Systemic therapy in advanced cutaneous squamous cell carcinoma （CSCC）: the Roswell Park experience and a review of the literature［J］. Am J Clin Oncol, 2016,39（6）:545⁃548. doi: 10.1097/COC.000000000 0000088.
［66］	Harwood CA, Leedham⁃Green M, Leigh IM, et al. Low⁃dose retinoids in the prevention of cutaneous squamous cell carcinomas in organ transplant recipients: a 16⁃year retrospective study［J］. Arch Dermatol, 2005,141（4）:456⁃464. doi: 10.1001/archderm. 141.4.456.
［67］	Bavinck JN, Tieben LM, Van der Woude FJ, et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double⁃blind, placebo⁃controlled study［J］. J Clin Oncol, 1995,13（8）:1933⁃1938. doi: 10.1200/JCO.1995.13.8.1933.
［68］	Zhao Y, Zhu Y, Wang H, et al. Case report: successful treatment of cutaneous squamous cell carcinoma in three patients with a combination of acitretin and clarithromycin［J］. Front Oncol, 2021,11:650974. doi: 10.3389/fonc.2021.650974.
［69］	Fox E, Elghobashy M, Hamad H, et al. Oral retinoid, acitretin, is effective in the management of resistant recurrent vulval verrucous carcinoma: a case report［J］. J Obstet Gynaecol Res, 2020,46（10）:2179⁃2184. doi: 10.1111/jog.14390.
［70］	Robertson SJ, Bashir SJ, Pichert G, et al. Severe exacerbation of multiple self⁃healing squamous epithelioma （Ferguson⁃Smith disease） with radiotherapy, which was successfully treated with acitretin［J］. Clin Exp Dermatol, 2010,35（4）:e100⁃e102. doi: 10.1111/j.1365⁃2230.2009.03668.x.
［71］	Yerebakan O, Ermis O, Yilmaz E, et al. Treatment of arsenical keratosis and Bowen′s disease with acitretin［J］. Int J Dermatol, 2002,41（2）:84⁃87. doi: 10.1046/j.1365⁃4362.2002.01372.x.
［72］	Ahmed SR, Petersen E, Patel R, et al. Cemiplimab⁃rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma［J］. Expert Rev Clin Pharmacol, 2019,12（10）:947⁃951. doi: 10.1080/17512433.2019.1665026.
［73］	Foote MC, McGrath M, Guminski A, et al. Phase II study of single⁃agent panitumumab in patients with incurable cutaneous squamous cell carcinoma［J］. Ann Oncol, 2014,25（10）:2047⁃2052. doi: 10.1093/annonc/mdu368.
［74］	Carlson CL. Effectiveness of the World Health Organization cancer pain relief guidelines: an integrative review［J］. J Pain Res, 2016,9:515⁃534. doi: 10.2147/JPR.S97759.
［75］	Flohil SC, van der Leest RJ, Arends LR, et al. Risk of subsequent cutaneous malignancy in patients with prior keratinocyte carcinoma: a systematic review and meta⁃analysis［J］. Eur J Cancer, 2013,49（10）:2365⁃2375. doi: 10.1016/j.ejca. 2013.03.010.
［76］	Levine DE, Karia PS, Schmults CD. Outcomes of patients with multiple cutaneous squamous cell carcinomas: a 10⁃year single⁃institution cohort study［J］. JAMA Dermatol, 2015,151（11）:1220⁃1225. doi: 10.1001/jamadermatol.2015.1702.
［77］	Brantsch KD, Meisner C, Schönfisch B, et al. Analysis of risk factors determining prognosis of cutaneous squamous⁃cell carcinoma: a prospective study［J］. Lancet Oncol, 2008,9（8）:713⁃720. doi: 10.1016/S1470⁃2045（08）70178⁃5.

[1]	GAO Ying, LI Chun-ying, MA Cui-ling, YIN He-hui, GAO Tian-wen. Expression of Double-stranded RNA-dependent Protein Kinase in Malignant Melanoma and Ordinary Nevi[J]. Chinese Journal of Dermatology, 2005, 38(12): 748 -750 .
[2]	. [J]. Chinese Journal of Dermatology, 2005, 38(12): 762 -763 .
[3]	. [J]. Chinese Journal of Dermatology, 2005, 38(12): 770 -771 .
[4]	廖列辉, 张锡宝, 范瑞强, 刘文静. [J]. Chinese Journal of Dermatology, 2005, 38(12): 761 .
[5]	. [J]. Chinese Journal of Dermatology, 2005, 38(12): 777 -778 .
[6]	ZHANG Ru-zhi, ZHU Wen-yuan, XIA Ming-yu, WANG Da-guang, MA Hui-jun. Ultrastructural Characteristics of Amelanotic Melanocytes from Human Hair Follicles[J]. Chinese Journal of Dermatology, 2005, 38(11): 671 -673 .
[7]	LIU Wei, JIANG Xian, CHEN Hui-li, LI Li, DENG CI-bing, LI Yong. in vitro Effect of High Intensity Blue Light on Bacteria Isolated from Patients with Acne Vulgaris[J]. Chinese Journal of Dermatology, 2005, 38(11): 683 -684 .
[8]	. [J]. Chinese Journal of Dermatology, 2005, 38(11): 693 -694 .
[9]	. [J]. Chinese Journal of Dermatology, 2005, 38(11): 697 -698 .
[10]	房婕, 韩德平, 顾军, 郭峰, 花美仙. [J]. Chinese Journal of Dermatology, 2005, 38(11): 699 -700 .

[1]	Wang Zhaoyang, Chen Anwei, Xiang Xin, Luo Xiaoyan, Xu Zigang, Wang Hua, Ma Lin. An investigation into the current situation of pediatric psoriasis based on the information systems from two children′s hospitals [J]. Chinese Journal of Dermatology, 2022, 55(3): 246-250.
[2]	Lyu Ling, Lyu Xiaoyan. Dermatomyositis with malignancy: an update [J]. Chinese Journal of Dermatology, 2022, 55(3): 276-279.
[3]	Li Suo, Xiang Ruiyu, Li Zhiliang, Jing Ke, Wang Yuan, Zhang Hanmei, Feng Suying. Evaluation of the value of indirect immunofluorescence on salt-split skin in the diagnosis of bullous pemphigoid [J]. Chinese Journal of Dermatology, 2022, 55(3): 235-237.
[4]	Xu Congcong, Chen Hao. The research progress of PI3K/Akt/mT0R signaling pathway in cutaneous squamous cell carcinoma [J]. Chinese Journal of Dermatology, 2022, 55(3): 264-267.
[5]	Han Xiaofeng, Sun Juan, Qiu Lei, Wei Li, Ma Lin. Analysis of clinical and pathological features of 29 cases of perforating pilomatricoma [J]. Chinese Journal of Dermatology, 2022, 55(3): 196-199.
[6]	Writing committee expert group on “diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement”. Diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement （2022） [J]. Chinese Journal of Dermatology, 2022, 55(3): 187-195.
[7]	Zhang Guoyi, Gong Xiangdong, Zhu Bokun, Liu Chuanxia, Jing Linghua, Xu Jinyu. Patterns of skin diseases among outpatients attending Hospital of Dermatology of Chinese Academy of Medical Sciences in 2019 [J]. Chinese Journal of Dermatology, 2022, 55(2): 150-152.
[8]	Yan Shi, Zhou Xiaoying, Luo Xiaoyan, Ren Faliang, Jiang Wei, Niu Linlin, Wang Hua, Bai Xiaoming. Construction of a Spink5 conditional knockout mouse model and analysis of its phenotype [J]. Chinese Journal of Dermatology, 2022, 55(2): 95-101.
[9]	Wang Xiaoyan, Zhang Jiawen, Liu Yunyi, Liu Yixuan, Jiang Peiyu, Li Min, Meng Tao, Xu Yang. Skin imaging and noninvasive measurements of rosacea [J]. Chinese Journal of Dermatology, 2022, 0(1): 20200939-e20200939.
[10]	Cheng Bihong, Dou Xia. Diagnosis and classification of chronic prurigo [J]. Chinese Journal of Dermatology, 2022, 0(1): 20210130-e20210130.
[11]	Wang Yuan, Yu Meiwen, Xiang Ruiyu, Li Suo, Li Zhiliang, Jin Ke, Zhang Hanmei, Feng Suying. Optimization of indirect immunofluorescence on salt-split skin and its application in detection of bullous pemphigoid antibodies [J]. Chinese Journal of Dermatology, 2022, 55(1): 12-15.
[12]	Zhang Ying, Gan Lu, Li Siqi, Li Yan, Song Hao, Shao Xuebao, Zhang Wei, Xu Xiulian, Jiang Yiqun, Zeng Xuesi, Chen Hao, Sun Jianfang. Clinicopathological and immunophenotypic analysis of 24 cases of transformed mycosis fungoides [J]. Chinese Journal of Dermatology, 2022, 55(1): 20-26.
[13]	Qu Yingying, Fang Jiaqi, Ouyang Mengting, Wang Mengyao, Huang Xianyin, Zheng Yue, Lai Wei, Xu Qingfang. Regulatory role of circIGF2BP3 in autophagy in photoaged dermal fibroblasts [J]. Chinese Journal of Dermatology, 2022, 55(1): 40-46.
[14]	Chinese Society of Dermatology, China Dermatologist Association. Consensus on the diagnosis and treatment of autoimmune subepidermal bullous diseases （2022） [J]. Chinese Journal of Dermatology, 2022, 55(1): 1-11.
[15]	Deng Lijun, Yang Qin, Lu Zhenzhong, Wu Ruibin. A case of cutaneous metaplastic synovial cyst [J]. Chinese Journal of Dermatology, 2022, 55(1): 57-60.

Consensus on diagnosis and treatment of cutaneous squamous cell carcinoma （2021）

PDF

Knowledge

Abstract

Cite this article

share this article

References ［77］

Related Articles 15

Metrics

Comments

Recommended 10